Radiolabeled Monoclonal Antibody Imaging Of Tumors And P

这些研究旨在开发检测和治疗恶性肿瘤的改进方法。我们小组对经过国家癌症研究所不同实验室初步筛选后似乎有希望的抗体进行临床前评估，并开发这些抗体用于临床应用。评价其药代动力学和剂量学的临床试验由本课题组进行。一项与Waldmann博士(PI)合作的放射免疫治疗试验正在进行中，在试验中我们使用了人源化的抗TAC单抗。一项与NCI合作的骨髓支持放射免疫治疗试验正在进行中。在PET中使用[F-18]FDG和[O-15]水进行肿瘤检测、随访和血流测量的各种方案正在进行中。我们已经开始了临床前研究，评估针对肿瘤治疗的前靶向抗体，并在动物肿瘤模型中展示了Y-90和Bi-213的治疗效果。

These studies are designed to develop improved methods for detecting and treating malignancies. Our group performs preclinical evaluation of antibodies that appear to be promising after initial screening by various laboratories at the National Cancer Institute and develops these antibodies for clinical application. The clinical trials evaluating their pharmacokinetics and dosimetry are performed by our group. A collaborative radioimmunotherapy trial with Dr. Waldmann (PI), in which we used humanized anti-tac monoclonal antibody, is ongoing. A collaborative radioimmunotherapy trial with bone marrow support is ongoing with NCI. Various protocols using [F-18] FDG in PET and [O-15] water for tumor detection, followup, and blood flow measurements are ongoing. We have begun preclinical studies evaluating pretargeting of antibodies for tumor therapy and have demonstrated therapeutic responses with Y-90 and Bi-213 in animal tumor models.